Edward J. Benz, Jr., MD, became the president and chief executive officer of the Institute in 2000 and also serves as chief executive officer of Dana-Farber/Partners CancerCare, director of Dana-Farber/Harvard Cancer Center, and as a trustee of Dana-Farber/Children's Hospital Cancer Care. Dr. Benz is presently the Richard and Susan Smith Professor of Medicine, professor of Pediatrics, professor of Pathology, and faculty dean for Oncology at Harvard Medical School.
He received a bachelor's degree, cum laude, from Princeton University, a medical degree, magna cum laude, from Harvard Medical School, and a master's degree (privatum) from Yale University.
Immediately prior to assuming the presidency of the Institute, Dr. Benz was chairman of the Department of Medicine at the Johns Hopkins University School of Medicine and the Sir William Osler Professor of Medicine.
Author of more than 200 articles, books, chapters, reviews, and abstracts, Dr. Benz is a past president of both the American Society of Hematology and the American Society of Clinical Investigation, and is currently an associate editor of the New England Journal of Medicine.
Dorothy E. Puhy became the Institute's chief operating officer in 2012. She previously served as chief financial officer and director for Fiscal Services since 1994, and executive vice president since 2004. Ms. Puhy is chief administrative officer of Dana-Farber/Partners CancerCare and treasurer of HealthCare Dimensions, Inc.
Prior to joining Dana-Farber, she was chief financial officer at New England Medical Center in Boston and a senior manager at Ernst and Whinney. Ms. Puhy received her bachelor's degree from the University of Pennsylvania and her business degree from its Wharton School.
Karen Bird joined Dana-Farber in 1999 and became chief financial officer and assistant treasurer in 2012. She had previously served as senior vice president for Finance since 2007. Prior to coming to Dana-Farber, Ms. Bird held positions at Faulkner Hospital, where she served as vice president for Network Development, and at New England Medical Center, where she was vice president of Finance. She received a bachelor's degree from Trinity College and a graduate degree from the Harvard School of Public Health.
Richard S. Boskey joined the Institute in 1999. He serves as assistant secretary of Dana-Farber Cancer Institute and Dana-Farber/Partners CancerCare, and secretary of the Dana-Farber Trust, Inc. and Dana-Farber/Children's Hospital Cancer Care. Previously, he served in various positions at Partners HealthCare and Massachusetts General Hospital, including deputy general counsel, and was an associate at the law firm Hill & Barlow. Mr. Boskey received his bachelor's degree from Brown University and his master's and law degrees from the University of Virginia.
Craig A. Bunnell, MD, MPH, MBA, became the Chief Medical Officer and Medical Director for Adult Ambulatory Oncology in 2012. Dr. Bunnell received his bachelor's degree, summa cum laude, from Colorado College after which he was a Thomas J. Watson Fellow in Stockholm, Sweden. He earned his medical degree from Harvard Medical School and his MPH from the Harvard School of Public Health. He also earned his MBA from the Sloan School of Management at the Massachusetts Institute of Technology. Dr. Bunnell completed his internship, residency and fellowship in hematology and oncology at Brigham and Women's Hospital, where he also served as Chief Medical Resident. Dr. Bunnell is a medical oncologist involved in research and the care of patients with breast cancer in the Susan F. Smith Center for Women's Cancers at Dana-Farber Cancer Institute.
James D. Griffin, MD, received his medical degree from Harvard Medical School in 1974. After residency training in internal medicine at Johns Hopkins Hospital, he completed a hematology fellowship at Massachusetts General Hospital and a medical oncology fellowship at Dana-Farber. In 1981, he joined the staff of Dana-Farber, where he currently is director of the Leukemia Program and chair of the Department of Medical Oncology.
From 1993 to 1998, Dr. Griffin was editor-in-chief of Blood. He is a professor of Medicine at Harvard Medical School and currently sits on the scientific advisory boards of the Lombardi Cancer Center at Georgetown University and the Johns Hopkins Cancer Center and Case Western Cancer Center.
William C. Hahn, MD, PhD, is chair of the Executive Committee for Research at Dana-Farber, where he has been engaged in clinical care and research since 1996. He is Chief of the Division of Molecular and Cellular Oncology in the Department of Medical Oncology and an Institute Member of the Broad Institute of MIT and Harvard. He received his AB in Biochemical Science, PhD in Immunology and MD all from Harvard University and completed his clinical training at Massachusetts General Hospital and Dana-Farber Cancer Institute. His research focuses on understanding how mutations cooperate in cancer initiation and progression to develop rational combination therapies.
Jay R. Harris, MD, received his medical degree from Stanford University in 1970. He trained in radiation oncology at the Harvard Joint Center for Radiation Therapy, and joined the Dana-Farber staff in 1977. Dr. Harris chairs the Department of Radiation Oncology at Dana-Farber, Brigham and Women's Hospital, and Boston Children's Hospital, which constitute the Longwood Radiation Oncology Center. He is also a professor of Radiation Oncology at Harvard Medical School.
Deborah Hicks joined Dana-Farber as the Senior Vice President for Human Resources in 2011. Prior to joining Dana-Farber, Hicks served as the associate dean and chief human resources officer at Harvard Medical School.
She joined Harvard Medical School in January 2009. Previously, Hicks was the vice president of Human Resources at Harvard Pilgrim Health Care (HPHC), joining HPHC in 1988 and becoming vice president of Human Resources and part of the leadership team in 1999, where she was instrumental in supporting the organization during the turnaround of HPHC from receivership to profitability.
She currently serves as chair of the Board of the New England Human Resources Association, holds a master's degree in Counseling Psychology/Organizational Management from Antioch University, and a bachelor's degree from the University of Massachusetts at Amherst.
Joseph Jacobson, MD, joined Dana-Farber Cancer Institute in 2011 as the Institute's first Chief Quality Officer, overseeing clinical quality programs across Dana-Farber and its affiliates, and representing Dana-Farber in regional and national quality improvement efforts. He focuses on clinical process measurement and improvement, efficiency and effectiveness of care, and quality leadership development. He is also a member of and practicing physician in our Thoracic Oncology Program.
Before joining Dana-Farber, Dr. Jacobson served as the Chairman of Medicine at North Shore Medical Center. As part of the Partners Healthcare system, he co-developed and currently co-directs the Partners Clinical Process Improvement Leadership Program. He has an extensive track record in quality measurement and quality improvement, serving as a founding member of the American Society of Clinical Oncology (ASCO) Quality Oncology Practice Initiative, as co-developer of the ASCO/ONS Chemotherapy Safety Standards and as recent past Chair of the ASCO Quality of Care Committee.
Bruce E. Johnson, MD, became Dana-Farber’s Chief Clinical Research Officer in 2013. He previously was director of the Lowe Center for Thoracic Oncology at Dana-Farber/Brigham and Women’s Cancer Center. He is also Professor of Medicine at Harvard Medical School and an American Society of Clinical Oncology Translational Research Professor.
Johnson graduated from Harvard University and the University of Minnesota Medical School. His postdoctoral training was at the University of Chicago Hospitals and Clinics and the National Cancer Institute. In 1992, he became head of the Lung Cancer Biology Section, Medicine Branch, at the NCI, until 1998, when he joined Dana-Farber.
Johnson directs the Lung Cancer Program within the Dana-Farber/Harvard Cancer Center. His translational research is devoted to testing novel therapeutic agents for their efficacy against lung cancer and other thoracic malignancies with specific genomic changes.
Philip W. Kantoff, MD, became chair of Dana-Farber's newly formed Executive Committee for Clinical Research in 2013. He previously served as Chief Clinical Research Officer for the Institute. Dr. Kantoff received his medical degree from Brown University Medical School in 1979 and completed his internship and residency in internal medicine at New York University Hospital and Bellevue Hospital. After four years conducting gene therapy research at the National Institutes of Health, Dr. Kantoff joined Dana-Farber in 1987, becoming director of the Lank Center for Genitourinary Oncology in 1988. He is Professor of Medicine at Harvard Medical School.
Dr. Kantoff is chief of the Division of Solid Tumor oncology at Dana-Farber. In addition, he is the leader of the Dana-Farber/Harvard Cancer Center Prostate Cancer Program and director of the prostate cancer Specialized Program of Research Excellence (SPORE).
Elizabeth A. Liebow, who joined Dana-Farber in 2004, is responsible for planning and business development for clinical services at Dana-Farber, as well as operational oversight of Dana-Farber's satellite locations and physician practices. Most notably, she directed the development of Dana-Farber's four satellite clinics and acquisition of eight physician practice sites, facilitated clinical operations planning for the Yawkey Center for Cancer Care, and oversaw strategic clinical growth planning efforts.
Ms. Liebow is currently focused on developing new partnerships with additional community sites and integrated delivery systems, continuing clinical growth on Dana-Farber's main campus, expanding care beyond New England, and improving efficiency and cost effectiveness in the community-based sites.
Ms. Liebow holds a Master of Science in Health Policy and Management from the Harvard School of Public Health and a BA in Economics from Brandeis University.
Maria Megdal joined Dana-Farber Cancer Institute as the Vice President for Facilities Management and Real Estate in 2008 and was named Senior Vice President for Institute Operations in 2012.
Before joining Dana-Farber, Ms. Megdal served as Vice President for Corporate Real Estate Services at Saint Vincent Catholic Medical Centers of New York. Prior to Saint Vincent's, Ms. Megdal held various management roles at Memorial Sloan-Kettering Cancer Center after completing her administrative residency there.
Ms. Megdal holds a masters in health administration from Cornell University and a bachelors degree in physical anthropology from Rutgers University. She is a longtime member of several alumni boards at Cornell where she serves as adjunct lecturer on facilities planning.
Drew Memmott joined Dana-Farber in 2014 as the Senior Vice President for Research Administration and the Associate Director for Administration for the Dana-Farber/Harvard Cancer Center. Prior to joining Dana-Farber, Mr. Memmott served as the Associate Director for Administration for the Mayo Clinic Cancer Center and as a Director for Research Administration at Columbia University Medical Center. Mr. Memmott received his bachelor's degree from the University of Utah and graduate degrees from the University of Washington and Columbia University.
Lee M. Nadler, MD, received his medical degree from Harvard Medical School in 1973. After residency training at Columbia-Presbyterian Medical Center, and training at the National Cancer Institute in tumor immunology, he completed a medical oncology fellowship at Dana-Farber, where he joined the staff in 1980. During his tenure at Dana-Farber, he has served as chief of the Division of Hematologic Malignancies and was the first chair of the Department of Adult Oncology. Dr. Nadler is the Virginia and D.K. Ludwig Professor of Medicine at Harvard Medical School and the Pan Mass Challenge Senior Investigator at Dana-Farber.
Stuart H. Orkin, MD, received his medical degree in 1972 from Harvard Medical School, followed by postdoctoral research at the National Institutes of Health and clinical training in pediatrics and hematology-oncology at Children's Hospital Boston and Dana-Farber, where he joined the faculty in 1978. Dr. Orkin is a Howard Hughes Medical Institute Investigator and the David G. Nathan Professor of Pediatrics at Harvard Medical School. Over the past decade, his laboratory has defined critical nuclear regulators of hematopoiesis.
Susan S. Paresky joined the Institute in 1997. Prior to this, she was associate dean for Development at the Harvard School of Public Health, where she executed the school's fundraising program as part of Harvard University's $2 billion campaign. She has also held senior positions at Brandeis University and Wheaton College. Ms. Paresky received her business degree from Simmons School of Management and her bachelor's degree from Wheaton College, where she served as a trustee for many years and received an honorary degree in 2011.
Patricia Reid Ponte, RN, DNSc, FAAN, also serves as the nursing director of the Hematology/Oncology, Bone Marrow Transplant Program at Brigham and Women's Hospital and as the cancer center nurse leader for Dana-Farber/Partners CancerCare. She received her bachelor's degree in nursing from the University of Massachusetts, Amherst, and her master's and doctorate degrees from Boston University. Dr Reid Ponte completed a three year Robert Wood Johnson Nurse Executive Fellowship in 2004 and was inducted into the American Academy of Nursing.
Barrett J. Rollins, MD, PhD, received his doctoral degree in 1979 and medical degree in 1980 from Case Western Reserve University and completed his internship and residency in internal medicine at Beth Israel Hospital, Boston. He then performed clinical and research fellowships in medical oncology at Dana-Farber and joined the Institute's faculty in 1986. Dr. Rollins is currently Professor of Medicine at Harvard Medical School.
Stephen E. Sallan, MD, joined the institute in 1973 as a trainee before becoming a member of the staff in the Department of Pediatric Oncology. He was named chief of staff and chairman of the Medical Staff Executive Committee in 1995, and chief of staff emeritus in 2012. Dr. Sallan received his undergraduate and medical degrees from Wayne State University. He is presently a professor of Pediatrics at Harvard Medical School, and was named the Quick Family Senior Investigator in 2002.
Steven R. Singer joined the Institute in 1997. He previously served as director of Communications and Public Affairs and adjunct lecturer at Harvard University's John F. Kennedy School of Government. He has worked as a press secretary in the U.S. House of Representatives, and is past chair of the National Cancer Institute's Public Affairs Network. Mr. Singer received his bachelor's degree from Colby College and a master's degree in public administration from Harvard University's Kennedy School.
Scott J. Swanson, MD, joined Dana-Farber as Chief Surgical Officer in 2008. He is the Disease Center Leader of the Thoracic Oncology Program, and leads a multidisciplinary group focused on optimizing the experience and outcome for patients with thoracic malignancy. Dr. Swanson is also director of the Minimally Invasive Thoracic Surgery Program at Brigham and Women’s Hospital, and Professor of Surgery at Harvard Medical School. He received a bachelor’s degree, magna cum laude, from Amherst College, and a medical degree from Harvard Medical School.
Annick Van den Abbeele, MD, received her BA and MD from the Université Catholique de Louvain in Belgium. Following a residency in Pediatrics at the Université Catholique de Louvain and a Neonatology fellowship at Vanderbilt University Medical Center in Nashville, TN, she completed a residency in Nuclear Medicine and a fellowship in Radiology at Brigham and Women's Hospital, Boston, MA and Harvard Medical School, followed by seven years in basic sciences research. In 1994, Dr. Van den Abbeele assumed the position of Director of Nuclear Medicine at the Dana-Farber Cancer Institute, and in 2004 became the Clinical Director of Radiology. In 2006, she was promoted to Chief of the Department of Imaging. She has been a faculty member at Harvard Medical School since 1987.
Eric P. Winer, MD, is chair of the Executive Committee for Clinical Programs. He is chief of the Division of Women's Cancers and director of the Breast Oncology Center at Dana-Farber/Brigham and Women's Cancer Center, and one of the leaders of the Institute's Susan F. Smith Center for Women's Cancers. In addition, he is director of the Dana-Farber/Harvard Cancer Center (DF/HCC) SPORE in Breast Cancer and Professor of Medicine at Harvard Medical School.
Dr. Winer's BA and MD degrees are from Yale University. He was a physician and associate professor of medicine at Duke University School of Medicine before coming to Dana-Farber in 1997.
Joanne Wolfe, MD, MPH, is the interim chair of the Department of Psychosocial Oncology and Palliative Care. She received her BSc from McGill University, her MD from Harvard Medical School, and her MPH from the Harvard School of Public Health. Dr. Wolfe completed her internship and residency at Boston Children's Hospital, where she also served as chief resident. She completed a fellowship in pediatric hematology/oncology at Dana-Farber/Boston Children's and joined the faculty in 1997. Dr. Wolfe is board-certified in Pediatric Oncology and Hospice and Palliative Medicine. She is an associate professor of Pediatrics at Harvard Medical School. Her research focuses on easing distress and enhancing well-being in children with advanced cancer and their families.
Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215 | Call us toll-free: